Denmark – Novo Nordisk today revealed ground-breaking findings from the real-world STEER study, showing that in patients with obesity and established cardiovascular disease, Wegovy® (semaglutide 2.4 mg) significantly lowers the risk of major adverse cardiovascular events (MACE) by 57% when compared to tirzepatide. This strong data supports Wegovy®’s cardiovascular advantages and establishes it as a top therapy choice for this high-risk patient group.
Key Findings from the STEER Study
Wegovy® and tirzepatide are compared side by side in the STEER study, a real-world evidence analysis. The time to the first occurrence of MACE, a composite of heart attack, stroke, or all-cause death, was the main outcome.
- Compared to tirzepatide, patients receiving continuous Wegovy® medication had a 57% higher reduction in MACE risk.
- Compared to tirzepatide users, all patients treated with Wegovy® had a 29% lower incidence of MACE, regardless of medication adherence.
- In the continuous treatment analysis, there were substantially fewer cardiovascular events (15 occurrences) in the Wegovy® group than in the tirzepatide group (39 events).
These findings from the STEER study align with the historic SELECT trial, which showed that Wegovy® reduced MACE risk by 20%.
Read More: Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment
Our landmark trial, SELECT, showed that Wegovy® is associated with a significant 20% risk reduction of cardiovascular events, backed up with even greater risk reductions in the real-world studies SCORE and STEER. The results are clear – STEER demonstrates that Wegovy® cuts the risk of heart attack, stroke or death by 57% compared to tirzepatide,
This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes.
Ludovic Helfgott
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
About STEER study
The effectiveness of tirzepatide and Wegovy® (semaglutide 2.4 mg) in preventing Major Adverse Cardiovascular Events (MACE) in adults with established cardiovascular disease (CVD) and overweight or obesity who did not have a history of diabetes was compared in the real-world, retrospective, observational STEER study. The purpose of the study was to determine how well these two well-known weight-loss drugs work outside of a controlled clinical trial in a typical clinical context. The study’s results were presented in Madrid, Spain, during the 2025 Congress of the European Society of Cardiology (ESC).
